Foresite Capital Management VI LLC

CIK 0002013341 · Q2 2026

13F Equity AUM

$642.6M

+39.6% QoQ

Positions

+6 QoQ

AUM Rank

#3,176

Top 36%

Skill Alpha (FF)

—

Building track record (6q)

Quarters Tracked

~1 years

Portfolio Concentration

Top 5: 61.5%Top 10: 81.5%Top 20: 99.5%

CGON26.2%

ALMS18.6%

Seaport Therapeutics, Inc.6.0%

DNLI5.6%

TCE25.1%

AGIO4.5%

CRVS4.3%

Parabilis Medicines, Inc.4.3%

GHRS3.9%

JBIO3.1%

Others (13)18.5%

HHI (Herfindahl-Hirschman Index) measures portfolio concentration. Low (<1500) = diversified, Moderate (1500-2500), High (>2500) = concentrated bets.

Sector Allocation

Healthcare89.1%

Unclassified10.9%

Portfolio weight by GICS sector based on latest 13F filing. Sectors below 2% are grouped as “Other.”

Position Sizing

Positions: 23Median: 2.61%Avg: 4.35%

0–0.5%

4(1.1%)

0.5–1%

0(0.0%)

1–3%

9(17.4%)

3–5%

5(20.1%)

5%+

5(61.5%)

Count of positions per weight bucket — (%) = combined portfolio weight

Loading summary cards...

Portfolio Overlap

Shared: 0Unique: 23vs 20 funds

0%Low

Fund positions

Consensus CUSIPs

Jaccard similarity of this fund’s portfolio vs the consensus of top 20 funds by AUM. Low (<15%) = contrarian, Moderate (15-40%), High (>40%) = follows the crowd.

Loading overlap analysis...

Position Changes This Quarter

New8Increased6Decreased1Exited2

New Positions

Seaport Therapeutics…6.0%

+1.8M

Parabilis Medicines,…4.3%

+999K

BEAM1.8%

+330K

AVBP1.6%

+301K

AURA1.5%

+1.3M

Research Alliance Co…0.5%

+300K

Kailera Therapeutics…0.1%

+38K

IRON0.0%

+970

Increased

GHRS3.9%

+625K(+198%)

JBIO3.1%

+567K(+177%)

TCE25.1%

+564K(+178%)

AGIO4.5%

+260K(+50%)

DNLI5.6%

+187K(+15%)

CGON26.2%

+148K(+7%)

Decreased

NERV1.7%

-1,016(-0%)

Exited

CNTA

-1,364,019

OKUR

-1,445,783

Quarter-over-quarter changes compared to prior 13F filing. New = first appearance; Exited = no longer held.

Loading position changes...

Holdings

Loading holdings...